{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:45Z","timestamp":1786207365449,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82072736"],"award-info":[{"award-number":["No. 82072736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82003205"],"award-info":[{"award-number":["82003205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373123\uff0c82473175"],"award-info":[{"award-number":["82373123\uff0c82473175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1245\/s10434-026-19837-1","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:09:27Z","timestamp":1780762167000},"page":"8323-8334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Concomitant Proton Pump Inhibitor Use on Oncologic Outcomes of Neoadjuvant Chemoimmunotherapy in Locally Advanced Gastric Cancer: A Multicenter Real-World Study"],"prefix":"10.1245","volume":"33","author":[{"given":"Xiong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-qiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo-fei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-xiong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"5","key":"19837_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338\u201349.","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"19837_CR2","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin."},{"key":"19837_CR3","doi-asserted-by":"publisher","first-page":"104082","DOI":"10.1016\/j.critrevonc.2023.104082","volume":"198","author":"C Wei","year":"2024","unstructured":"Wei C, Du X, Hu J, et al. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: a systematic review with meta-analysis. Crit Rev Oncol Hematol. 2024;198:104082.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"10294","key":"19837_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet."},{"issue":"10","key":"19837_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol."},{"issue":"4","key":"19837_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","volume":"33","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33(4):570\u201380.","journal-title":"Cancer Cell."},{"key":"19837_CR7","first-page":"12","volume":"9","author":"J Mao","year":"2012","unstructured":"Mao J, Wang D, Long J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2012;9:12.","journal-title":"J Immunother Cancer."},{"key":"19837_CR8","doi-asserted-by":"publisher","first-page":"1070076","DOI":"10.3389\/fimmu.2023.1070076","volume":"14","author":"S Lopes","year":"2023","unstructured":"Lopes S, Pabst L, Dory A, et al. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis Front Immunol. 2023;14:1070076.","journal-title":"A meta-analysis. Front Immunol."},{"issue":"11","key":"19837_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.6004\/jnccn.2025.7070","volume":"23","author":"C Niu","year":"2025","unstructured":"Niu C, Zhang J, Singh H, et al. Impact of concomitant proton pump inhibitor use on the efficacy of immune checkpoint inhibitors across multiple cancer types. J Natl Compr Canc Netw. 2025;23(11):437\u201343.","journal-title":"J Natl Compr Canc Netw."},{"issue":"5","key":"19837_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/1750743X.2025.2491300","volume":"17","author":"M Shibano","year":"2025","unstructured":"Shibano M, Takahashi M, Nakatsukasa H, et al. Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer. Immunotherapy. 2025;17(5):331\u20138.","journal-title":"Immunotherapy."},{"key":"19837_CR11","doi-asserted-by":"publisher","first-page":"175883592211117","DOI":"10.1177\/17588359221111703","volume":"14","author":"B Chen","year":"2022","unstructured":"Chen B, Yang C, Dragomir MP, et al. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022;14:17588359221111704.","journal-title":"Ther Adv Med Oncol."},{"issue":"7","key":"19837_CR12","doi-asserted-by":"publisher","first-page":"e2322915","DOI":"10.1001\/jamanetworkopen.2023.22915","volume":"6","author":"H Kawachi","year":"2023","unstructured":"Kawachi H, Yamada T, Tamiya M, et al. Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non-small cell lung cancer. JAMA Netw Open. 2023;6(7):e2322915.","journal-title":"JAMA Netw Open."},{"issue":"8","key":"19837_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ijc.33892","volume":"150","author":"YH Baek","year":"2022","unstructured":"Baek YH, Kang EJ, Hong S, et al. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors. Int J Cancer. 2022;150(8):1291\u2013300.","journal-title":"Int J Cancer."},{"key":"19837_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2023.02.011","volume":"184","author":"A Wada","year":"2023","unstructured":"Wada A, Enokida T, Okano S, et al. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2023;184:30\u20138.","journal-title":"Eur J Cancer."},{"key":"19837_CR15","first-page":"9","volume":"4","author":"K Homicsko","year":"2022","unstructured":"Homicsko K, Dummer R, Hoeller C, et al. Proton pump inhibitor use and efficacy of nivolumab and ipilimumab in advanced melanoma. Cancers (Basel). 2022;4:9.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"19837_CR16","doi-asserted-by":"publisher","first-page":"1927313","DOI":"10.1080\/2162402X.2021.1927313","volume":"10","author":"M Abdelrahim","year":"2021","unstructured":"Abdelrahim M, Mamlouk O, Lin H, et al. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10 year single-institution analysis. Oncoimmunology. 2021;10(1):1927313.","journal-title":"Oncoimmunology."},{"key":"19837_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/jitc-2021-002421","volume":"9","author":"A Cortellini","year":"2021","unstructured":"Cortellini A, Di Maio M, Nigro O, et al. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021;9:42.","journal-title":"J Immunother Cancer."},{"issue":"20","key":"19837_CR18","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","volume":"26","author":"AM Hopkins","year":"2020","unstructured":"Hopkins AM, Kichenadasse G, Karapetis CS, et al. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res. 2020;26(20):5487\u201393.","journal-title":"Clin Cancer Res."},{"issue":"4s","key":"19837_CR19","doi-asserted-by":"publisher","first-page":"101961","DOI":"10.1016\/j.jormas.2024.101961","volume":"125","author":"S Kikuta","year":"2024","unstructured":"Kikuta S, Abe Y, Hino K, et al. What prognostic factors have impacted the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic oral cancer? J Stomatol Oral Maxillofac Surg. 2024;125(4s):101961.","journal-title":"J Stomatol Oral Maxillofac Surg."},{"key":"19837_CR20","doi-asserted-by":"publisher","first-page":"1103320","DOI":"10.3389\/fonc.2023.1103320","volume":"13","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Cui H, Wang S, et al. Combining neoadjuvant chemotherapy with PD-1\/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1103320.","journal-title":"Front Oncol."},{"issue":"2","key":"19837_CR21","doi-asserted-by":"publisher","first-page":"109517","DOI":"10.1016\/j.ejso.2024.109517","volume":"51","author":"X Sun","year":"2025","unstructured":"Sun X, Li X, Zhao S, et al. Which surrogate endpoint best predict survival in locally advanced gastric cancer patients undergoing neoadjuvant chemoimmunotherapy followed by surgery? A multicenter retrospective study. Eur J Surg Oncol. 2025;51(2):109517.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"19837_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740\u20138.","journal-title":"Gut."},{"issue":"6371","key":"19837_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science."},{"issue":"5","key":"19837_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","volume":"71","author":"WM de Vos","year":"2022","unstructured":"de Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020\u201332.","journal-title":"Gut."},{"issue":"5","key":"19837_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749\u201356.","journal-title":"Gut."},{"issue":"5","key":"19837_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2036.2012.05201.x","volume":"36","author":"MW Hess","year":"2012","unstructured":"Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405\u201313.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"19837_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12957-025-04084-7","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Sun X, Lin Y, et al. Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy. World J Surg Oncol. 2025;23(1):432.","journal-title":"World J Surg Oncol."},{"issue":"2","key":"19837_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000484688","volume":"97","author":"A Shiotani","year":"2018","unstructured":"Shiotani A, Katsumata R, Gouda K, et al. Hypergastrinemia in long-term use of proton pump inhibitors. Digestion. 2018;97(2):154\u201362.","journal-title":"Digestion."},{"issue":"7634","key":"19837_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","volume":"336","author":"I Forgacs","year":"2008","unstructured":"Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2\u20133.","journal-title":"BMJ."},{"issue":"1","key":"19837_CR30","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1136\/gutjnl-2024-332154","volume":"74","author":"AK Dutta","year":"2024","unstructured":"Dutta AK, Sharma V, Jain A, et al. Inappropriate use of proton pump inhibitors in clinical practice globally: a systematic review and meta-analysis. Gut. 2024;74(1):e5.","journal-title":"Gut."},{"issue":"10","key":"19837_CR31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol."},{"key":"19837_CR32","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023; 26 (1): 1-25.","DOI":"10.1007\/s10120-022-01331-8"},{"issue":"5","key":"19837_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2025;23(5):169\u201391.","journal-title":"J Natl Compr Canc Netw."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19837-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:49:00Z","timestamp":1786204140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19837-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19837"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19837-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare they have no conflicts of interest regarding this study.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study protocol was reviewed and approved by the Institutional Ethics Committee of the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (approval no.: 2020-0447). Written informed consent was obtained from all the patients.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}